Adult acute lymphoblastic leukemia in a resource-constrained setting: outcomes after expansion of genetic evaluation

Figures & data

Table 1. Baseline features of patients (n = 104).

Age – median (range, IQR)	37.5 (15-79,23-57.25)
Sex	Male: 57.7% (60/104)
BMI (kg/m2) – median (range, IQR)	23.8 (15.7-48.4, 21-27.8)
Obesity – % (n)	17.3 (18)
Extramedullary disease (excluding CNS disease)	23.9%
Immunophenotype – % (n)	B: 75 (78) T: 20.2 (21) Ambiguous lineage: 4.8 (5)
CD34 expression	Positive: 70.5%
Immunophenotypic classification (EGIL) – % (n)	Pro-B: 7.7 (6) Common B: 67.9 (53) Pre-B: 24.4 (19)
Initial WBC (x10^9/L) – median (range, IQR)	13.9 (0.31–252.4, 5-119.7)
Fibrinogen (mg/dL) – median (range, IQR)	290 (101-990, 191.5-434)
D-dimer (IU/L) – median (range, IQR) *Missing =  40.9%	4053 (190-55093,1412-10000)

Figure 1. Graphic displaying genetic baseline features of B-lineage ALL cohort.

Figure 2. OS Kaplan-Meier curve according to the initial regimen.

Figure 3. OS and EFS curves according to the genetic subset within B-lineage cases.

Table 2. Treatment and outcomes of patients with ‘Ph-like’ alterations.

Sex, age (years)	Genetic alteration	Initial WBC (x10^9/L)	Initial regimen	Outcome
Male, 27	IKZF1 deletion	5.9	aBFM	Alive, negative MRD, under maintenance (2 years)
Male, 31	FGFR1 fusion	0.3	aBFM	Primary refractory, response after inotuzumab ozogamicin, allo-HCT and death post relapse 10 months after
Male, 22	PDGFRB fusion, IKZF1 deletion	31.6	aBFM	Died during induction remission from infection.
Male, 19	ABL1 fusion	119.7	aBFM	Primary refractory, response after nilotinib, allo-HCT (died during transplantation)
Male, 50	IGH-CRLF2 fusion	8.03	HCVAD	Death from febrile neutropenia 4 months from diagnosis
Female, 24	IKZF1 deletion	15.05	HCVAD	Persistent positive MRD, allo-HCT, remains under remission 2 years after the procedure
Female, 42	IGH-CRLF2 fusion	81.6	HCVAD	Persistent positive MRD, refused allo-HCT, remains alive 4 years from diagnosis.
Female, 69	IGH-CRLF2 fusion	47.2	aGRAALL-elderly	Death from febrile neutropenia 5 months from diagnosis
Female 25	P2RY8-CRLF2 fusion	14.8	aGRAALL-elderly	Refusal of blood transfusion, shortly relapsed after chemotherapy, salvaged with inotuzumab. Remains under remission for 16 months.